KR20240060820A - 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안 - Google Patents

혈전색전성 장애의 예방 및 치료를 위한 밀벡시안 Download PDF

Info

Publication number
KR20240060820A
KR20240060820A KR1020247012366A KR20247012366A KR20240060820A KR 20240060820 A KR20240060820 A KR 20240060820A KR 1020247012366 A KR1020247012366 A KR 1020247012366A KR 20247012366 A KR20247012366 A KR 20247012366A KR 20240060820 A KR20240060820 A KR 20240060820A
Authority
KR
South Korea
Prior art keywords
milvexian
daily dose
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247012366A
Other languages
English (en)
Korean (ko)
Inventor
존 스트로니
게리 피터스
마두 친탈라
크리스토퍼 네셀
리야나게 비드야 페레라
단시 리
조셉 엠. 뤼트겐
디에트마르 알프레드 세이페르트
샬럿 존스-버튼
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니, 얀센 파마슈티카 엔브이 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20240060820A publication Critical patent/KR20240060820A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247012366A 2021-09-17 2022-09-16 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안 Pending KR20240060820A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US63/245,522 2021-09-17
US202163278582P 2021-11-12 2021-11-12
US63/278,582 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
KR20240060820A true KR20240060820A (ko) 2024-05-08

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247012366A Pending KR20240060820A (ko) 2021-09-17 2022-09-16 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안

Country Status (11)

Country Link
US (1) US20250099466A1 (https=)
EP (1) EP4401736A1 (https=)
JP (1) JP2024534427A (https=)
KR (1) KR20240060820A (https=)
AU (1) AU2022345862A1 (https=)
CA (1) CA3232633A1 (https=)
CL (1) CL2024000776A1 (https=)
IL (1) IL310894A (https=)
MX (1) MX2024002857A (https=)
TW (1) TW202327607A (https=)
WO (1) WO2023043999A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) * 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
TW202506125A (zh) * 2023-04-19 2025-02-16 美商必治妥美雅史谷比公司 米爾維仙(milvexian)於治療及預防患有心血管或腦血管疾病之患者之血栓病況的用途
WO2024220803A1 (en) * 2023-04-19 2024-10-24 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation
EP4698172A1 (en) * 2023-04-19 2026-02-25 Bristol-Myers Squibb Company Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112021020257A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Also Published As

Publication number Publication date
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
IL310894A (en) 2024-04-01
JP2024534427A (ja) 2024-09-20
EP4401736A1 (en) 2024-07-24
CA3232633A1 (en) 2023-03-23
US20250099466A1 (en) 2025-03-27
WO2023043999A1 (en) 2023-03-23
TW202327607A (zh) 2023-07-16
MX2024002857A (es) 2024-03-21

Similar Documents

Publication Publication Date Title
KR20240060820A (ko) 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안
WO2009140092A1 (en) Maintenance of platelet inhibition during antiplatelet therapy
JP2022542514A (ja) 脳卒中の処置のためのｍｅｋ阻害剤
TW201022237A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
TW201031651A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
KR20240116816A (ko) 진행성 섬유화 간질성 폐질환 치료를 위한 새로운 치료제 병용물
JPWO2013089164A1 (ja) 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤
CN119816305A (zh) Milvexian在治疗或预防缺血性中风中的用途
JP2024543161A (ja) 進行性線維化を伴う間質性肺疾患を治療するための、新たな経口医薬組成物及び投与レジメン
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
JP6885649B2 (ja) 統合失調症の治療のためのイロペリドン
JP2008543853A (ja) プラスグレルのための薬剤投与計画
CN118302166A (zh) 用于预防及治疗血管栓塞病症的米尔维仙
CA2993858C (en) Combination of rivaroxaban and acetylsalicylic acid for reducing the risk of cardiovascular events
JP2008044871A (ja) 心血管疾患予防・治療剤
TW201219404A (en) Reversal agents for the anticoagulant effect
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
TW202506124A (zh) 米爾維仙(milvexian)於治療或預防患有急性冠狀動脈症候群之患者之不良腦血管事件或不良心血管事件的用途
CA3217490A1 (en) Masitinib for the treatment of castrate-resistant prostate cancer
MXPA04001174A (es) Tratamiento para lipodistrofia.
TW202241446A (zh) 治療方法
US20150065456A1 (en) Agent for treatment and prevention of cancer
JP2011528345A (ja) 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000